Cerity Partners
APGE

Cerity Partners’s Apogee Therapeutics APGE Stock Holding History

Cerity Partners’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,211
Closed -$213K – 2236
2024
Q1 		$213K Buy
+3,211
New +$140K ﹤0.01% 2077

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cerity Partners's APGE Position: Q2 2024 in Review

Cerity Partners sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 3,211 shares — an estimated $213K sold.

Cerity Partners first reported a position in APGE in Q1 2024 and held it in 1 quarter. The position peaked at $213K in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

  • Cerity Partners reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cerity Partners sold 3,211 Apogee Therapeutics shares in Q2 2024, an estimated $213K.
  • Cerity Partners first reported a position in Apogee Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cerity Partners's Apogee Therapeutics position peaked at $213K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on Cerity Partners's 13F filing for Q2 2024, filed 13 Aug 2024.